
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Neurosense Therapeutics Ltd (NRSN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NRSN (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $10.75
1 Year Target Price $10.75
2 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.71% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.78M USD | Price to earnings Ratio - | 1Y Target Price 10.75 |
Price to earnings Ratio - | 1Y Target Price 10.75 | ||
Volume (30-day avg) 3 | Beta 1.62 | 52 Weeks Range 0.67 - 2.60 | Updated Date 08/15/2025 |
52 Weeks Range 0.67 - 2.60 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.36 |
Earnings Date
Report Date 2025-08-01 | When - | Estimate -0.225 | Actual -0.09 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -303.9% | Return on Equity (TTM) -2478.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25479813 | Price to Sales(TTM) - |
Enterprise Value 25479813 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.16 | Shares Outstanding 24602400 | Shares Floating 12538862 |
Shares Outstanding 24602400 | Shares Floating 12538862 | ||
Percent Insiders 30.21 | Percent Institutions 0.74 |
Upturn AI SWOT
Neurosense Therapeutics Ltd
Company Overview
History and Background
Neurosense Therapeutics Ltd. is a biotechnology company focused on discovering and developing treatments for neurodegenerative diseases. Founded in 2016 and went IPO in 2020, it has milestones in progressing pipeline candidates through preclinical and early-stage clinical trials.
Core Business Areas
- Drug Development: Focuses on identifying and developing novel therapeutics for diseases like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's.
- Preclinical and Clinical Trials: Conducts research and clinical trials to evaluate the safety and efficacy of their drug candidates.
- Intellectual Property: Secures and maintains patents and other intellectual property rights to protect their drug candidates.
Leadership and Structure
The company's leadership team includes a CEO, CSO, and other executives with experience in drug development and the pharmaceutical industry. The organizational structure is typical of a biotechnology company, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- PrimeC: An investigational drug candidate for ALS. It is in Phase II clinical trials. Currently no market share information exists. Competitors include Mitsubishi Tanabe Pharma (Radicava), Amylyx Pharmaceuticals (Relyvrio) and Biogen (Tofersen).
- CogniTune: An investigational drug candidate for Alzheimer's disease and related cognitive impairment. Preclinical development stage. Currently no market share information exists. Competitors include Biogen (Aduhelm, Leqembi), Eli Lilly (Donanemab)
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing advancements in targeted therapeutics and personalized medicine, while facing challenges such as regulatory hurdles and competition. The Alzheimer's and ALS segments are particularly active, with unmet medical needs driving innovation.
Positioning
Neurosense is positioned as a biotechnology company developing novel therapeutics for neurodegenerative diseases, with a focus on innovative approaches.
Total Addressable Market (TAM)
The total addressable market for neurodegenerative disease therapies is estimated to be in the tens of billions of dollars. The TAM grows as the population ages. Neurosense Therapeutics is positioned to capture a portion of this TAM through its innovative drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in development
- Focus on unmet medical needs
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Early-stage company
- Limited commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial results
- Expansion into new therapeutic areas
- Government funding and grants
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- ABBV
- BIIB
- LLY
- AMTX
Competitive Landscape
Neurosense faces significant competition from established pharmaceutical companies with greater resources. Neurosense's competitive advantage lies in its novel drug candidates and innovative approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical trial advancement and partnership development.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst projections are not readily available.
Recent Initiatives: Neurosense is currently engaged in clinical trials for PrimeC and preclinical work for CogniTune
Summary
Neurosense Therapeutics is a biotechnology company with promising drug candidates in development for neurodegenerative diseases. While the company faces risks associated with clinical trials and competition, it also has opportunities to partner with larger companies and expand its pipeline. Its success hinges on the success of PrimeC and other therapeutic compounds. The company needs to focus on securing funding, advancing products in clinical trials, and establishing strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Public SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are based on available data and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neurosense Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-12-09 | Co-Founder, CEO & Director Mr. Alon Ben-Noon | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.neurosense-tx.com |
Full time employees 17 | Website https://www.neurosense-tx.com |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.